| Name | Manidipine dihydrochloride |
| Description | Manidipine dihydrochloride (Manidipine 2HCl) is a potent calcium channel blocker for Ca2+ current(IC50=2.6 nM). |
| Cell Research | The mitogenic effect is measured by the amout of [3H]thymidine incorporated into DNA of human MCs and by assessment of cell proliferation. In brief, 1 × 105 quiescent cells is seeded into a 25-mL cell culture bottle and kept in low serum medium (0.1% FCS). On the following day, the cells are preincubated for 3 hours with Manidipine (10 nM) followed by stimulation with PDGF-BB (10 ng/mL) or incubated with low serum medium abone. The medium is replaced each day, and the cells are counted at days 1, 3 and 5.(Only for Reference) |
| In vitro | At nanomolar concentrations, Manidipine effectively modulates gene transcription involved in the inflammatory transformation of mesangial cells. Manidipine inhibits the coronary artery (pIC50=9.3 nM) and renal artery (pIC50=9.1 nM). Additionally, Manidipine decreases Ca2+ flux at concentrations above 0.1 nM and blocks Ca2+ flux at 100 nM. |
| In vivo | In hypertensive rats, oral administration of Manidipine (3 mg/kg and 10 mg/kg) reduced systolic blood pressure in a dose-dependent manner. When administered at a dose of 10 mg/kg, Manidipine was able to normalize blood pressure within 1 to 3 hours post-administration. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 60 mg/mL (87.77 mM), Sonication is recommended.
|
| Keywords | Manidipine dihydrochloride | Manidipine Dihydrochloride | Manidipine | Inhibitor | inhibit | CV4093 | CV 4093 | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels |
| Inhibitors Related | Nisoldipine | Diltiazem hydrochloride | Levetiracetam | L-Ascorbic acid | L-Phenylalanine | D-Menthol | Ethyl cinnamate | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Nifedipine | Otilonium bromide |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
